Vitiligo Complicating chronic Hepatitis B patients treated with α-Interferon (Report of two cases)

Authors

  • A Shokoohi
  • SM Alavian
Abstract:

α-Interferon is an antiviral agent used in treatment of chronic hepatitis B. Triggering of the underlying autoimmune disease or exacerbation of pre-existing auto immune disease is documented with α-interferon, but there are few reports about occurrence of autoimmune disorders such as systemic lupus erythematosus, Vitiligo, hypo and hyperthyroidism after administration of α-interferon in the literature. We report here in two cases of chronic hepatitis B treated with a-interferon, who developed Vitiliginous lesions. These lesions disappeared within 3 to 6 months after discontinuing α-interferon therapy. Until now, the occurrence of vitiligo after administration of α-interferon in chronic hepatitis B has not been reported.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Effect of Interferon-α and Combined Interferon-α with Lamivudine Treatment on Anthropometric Measurements in Children with Chronic Hepatitis B.

ated in each group, TST and SST Z-scores of HBeAg-positive patients were significantly higher than those in anti-HBe positive patients in group 1 ( p < 0.05). No statistically significant differences were observed in the other Z-scores ( p > 0.05). When HBeAg-positive patients and antiHBe-positive patients were compared in group 2, TST, SST, MAC, and MAMA Z-scores were not found to be statistic...

full text

Treatment of Chronic Hepatitis B with Tenofovir

Background:Tenofovir is among the first-line treatments for chronic hepatitis B (CHB) virus infection. We evaluated the efficacy of Tenofovir in the treatment of Iranian adult patients with CHB. Methods: In a retrospective study, we evaluated 154 HBsAg positive patients referred to Sadoughi hospital in Yazd-Iran for treatment ...

full text

Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir

Entecavir requires long-term administration. Pegylated interferon (PEG-IFN) therapy leads to significant reduction of hepatitis B surface antigen (HBs Ag) levels. This study aimed to assess the safety and efficacy of adding PEG-IFN-α-2a to entecavir toward cessation of entecavir. A total of 23 patients treated with entecavir underwent add-on PEG-IFN-α-2a therapy (90 μg per week) for 48 weeks. V...

full text

Serous Retinal Detachments Complicating Interferon-α and Ribavirin Treatment in Patients with Hepatitis C

PURPOSE To report the cases of two patients with chronic hepatitis C infection showing serous retinal detachments similar to Vogt-Koyanagi-Harada (VKH) disease. METHODS We reviewed the clinical records of two patients who were diagnosed with VKH-like disease during combined interferon-α (IFNα) and ribavirin treatment. RESULTS Interruption of IFNα and ribavirin treatment in association with ...

full text

The Study of Cerumen Hepatitis B Infection in Chronic Hepatitis B Patients by Real-Time PCR

Introduction: The hepatitis B is a viral infection that causes a big problem globally. About 2 billion people worldwide are infected and there are now about 400 million HBV-DNA carriers around the world. HBV infection is the ninth cause of death worldwide and infects about 350 million new cases each year in the world. HBV-DNA can be spotted in different body secretions and fluids, including se...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 5  issue 3

pages  45- 49

publication date 2002-04-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023